Enanta Shares Rise On Positive Data From Initial-Stage Covid-19 Study


Enanta Pharmaceuticals ENTA reported positive topline data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of orally administered single and multiple ascending doses of EDP-235 in healthy adult subjects.

EDP-235 is specifically designed to be a once-daily, oral antiviral treatment for COVID-19. EDP-235 was generally safe and well-tolerated in healthy subjects up to 400mg for up to seven days.

The data from the Phase 1 study demonstrated favorable safety, tolerability, and PK with strong exposure multiples over the EC90, thereby supporting the advancement of EDP-235 into a Phase 2 study using once-daily dosing, without ritonavir.

Jay R. Luly, President and Chief Executive Officer, commented: “"We are very pleased with the encouraging results from our Phase 1 study of EDP-235 showing that it was generally safe and well-tolerated up to a once-daily dose of 400mg, which provided plasma drug levels that were 6-fold and 12-fold over the plasma protein adjusted EC90 for the Alpha variant and the Delta variant, respectively. Moreover, EDP-235 is projected to have four times higher drug levels in lung tissue compared to plasma, which would drive exposure multiples to 24-fold and 48-fold for the respective variants.”

With this positive data readout, the company is planning to initiate a Phase 2 clinical study of EDP-235 in the fourth quarter, exploring doses of 200mg and 400mg once-daily, pending review with the regulatory agency.

Price Action: Enanta shares are trading around 4 percent at $51.59 on Friday at the time of publication.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechHealth CareSmall CapGeneralPositive Clinical Results
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!